You are viewing the site in preview mode

Skip to main content

Advertisement

Table 3 Outcomes with definitive chemoradiotherapy for stage III non-small cell lung cancer

From: A critical review of recent developments in radiotherapy for non-small cell lung cancer

Trial Inclusion Staging PET-CT Histology Treatment regimen in standard CRT arma RT technique N PTV (mean) Toxicity in standard CRT arm Outcomes
RTOG 0617 [58] Unresectable III 91 % 42/47 % squamous in 60/74 Gy arms 60 Gy Concurrent carboplatin-paclitaxel, followed by 2 cycles consolidation 46/47 % IMRT in 60/74 Gy arms (Remainder 3DCRT) 424 analyzable for radiation end-point 495/510 mL in the 60/74 Gy arm In 60 Gy arm: Grade ≥ 3 RP 7 % Grade ≥ 3 esophagitis 7 % Grade 5 toxicity 3 % In 60 Gy arm: Median OS 29 months 2-year OS 58 % 2-year LF 31 % 2-year DF 47 %
PROCLAIM [78] Nonsquamous III 82 % Non-squamous only 60–66 Gy Arm A: pemetrexed-cisplatin, pemetrexed consolidation Arm B: etoposide-cisplatin, non-pemetrexed consolidation 25 % IMRT (Remainder 3DCRT) 598 607/585 mL Grade ≥ 3 RP 1.8/2.6 % Grade ≥ 3 esophagitis 15.5/20.6 % Grade 5 toxicity 1.7/1 % Median OS 27/25 months Median PFS 11.4/9.8 months IFF (site of 1st failure) 42 % DF (site of 1st failure) 48 %
KCSG-LU05-04 [79] Unresectable III 92 % 32 % squamous 66 Gy Concurrent docetaxel-cisplatin Arm A: CRT-observation Arm B: CRT-docetaxel-cisplatin consolidation NR 437 eligible NR Grade ≥ 3 RP 1.2 % Grade ≥ 3 esophagitis 9.5 % Grade 5 toxicity 3.6 % during CRT, 2.9 % during consolidation Median OS 20.6/21.8 months Median PFS 8.1/9.1 months After median follow-up time of 51 months: DF 25 % LRR 25 % DF and LF 3 %
RTOG 9410 [129] Inoperable stage II-III 0 % 38 % squamous 63 Gy Cisplatin-Vinblastine 2DRT 610 N/A For CRT with early RT arm: Grade ≥ 3 esophagitis 22 % Grade ≥ 3 acute RP 4 % Grade 5 toxicity 2 % (as worst overall toxicity) For CRT with early RT arm: 5-year OS 16 % Median OS 17 months IFF only 25 % Out of field only 37 % Both IFF and out of field 10 %
Meta-analysis of 6 trials comparing CRT vs sequential CT/RT [130] Unresected stage III 0 % 46 % 60 Gy (2 trials), 66 Gy, (1 trial), 66 Gy in 24 fractions (1 trial), 56 Gy split course (1 trial), 48.5 Gy (split course of 36 Gy in 12 fractions, 7 days rest, 12.5 Gy in 5 fractions) Single agent low-dose cisplatin (2 trials), cisplatin-based doublet (3 trials), carboplatin (1 trials) 3DCRT in 1 trial Remainder 2DRT 603/602 in concurrent/sequential groups N/A Grade ≥ 3 esophagitis 18 % (concurrent CRT) Rates of acute RP and Grade 5 toxicity NR For concurrent CRT patients: 3-year OS 24 % 5-year OS 15 % 3-year LRF 28 % 5-year LRF 29 % 3-year DF 40 % 5-year DF 41 %
  1. Abbreviations CRT chemoradiotherapy, CT chemotherapy, RT radiotherapy, IMRT intensity modulated radiotherapy, PTV planning target volume, mL milliliters, N/A not applicable, RP radiation pneumonitis, OS overall survival, DFS disease free survival, IFF in-field failure, LF local failure, DF distant failure, LRR locoregional recurrence, NR not reported, 3DCRT three- dimensional conformal radiotherapy, 2DRT two-dimensional radiotherapy
  2. aAll RT standard fractionation